Rapid Therapeutic Science Laboratories, Inc. announced that it has entered into a securities purchase agreement with a purchaser for convertible debenture for gross proceeds of $350,000 on May 31, 2022. The debenture is issued at a discount of $61,764.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.005 USD | 0.00% | 0.00% | +21.95% |
1st Jan change | Capi. | |
---|---|---|
+21.95% | 94.93K | |
+45.15% | 6.38B | |
-14.00% | 4.59B | |
+9.54% | 3.39B | |
-8.99% | 3.2B | |
+50.03% | 2B | |
-6.97% | 1.7B | |
-0.31% | 1.65B | |
+50.00% | 1.55B | |
-10.61% | 1.58B |
- Stock Market
- Equities
- RTSL Stock
- News Rapid Therapeutic Science Laboratories, Inc.
- Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.35 million in funding